Coordination Chemistry of Anthracycline-Iron Complexes and Semiquinone Redox Cycling
Doxorubicin possesses a planar tetracyclic aglycone backbone containing a dihydroxyanthraquinone scaffold that coordinates transition metal ions [1]. Ferric iron, Fe(III), forms high-affinity complexes with doxorubicin at physiological pH, yielding a coordination complex exhibiting an overall association constant (Ka) approximating 10[6] for a 3:1 ligand-to-metal stoichiometry [1][2]. This coordination alters both the thermodynamic stability and the standard reduction potential of the anthracycline core [2]. Within human cardiac tissue, enzymatic one-electron reduction of the parent quinone moiety is driven by microsomal flavoproteins, including NADPH-cytochrome P450 reductase, endothelial nitric oxide synthase, and mitochondrial Complex I NADH dehydrogenase (NDUFV2 subunit) [1][2][3]. This univalent reduction yields an unstable doxorubicin semiquinone free radical intermediate [2].
Under normoxic physiological conditions, the semiquinone intermediate rapidly transfers its acquired electron to molecular oxygen (O₂), regenerating the parent quinone compound and producing steady-state fluxes of superoxide anion (O₂^{\bullet-}) [2]. This redox cycle achieves turnover rates that surpass baseline mitochondrial metabolic electron leak by three- to five-fold [1][2]. In parallel with flavoprotein-driven enzymatic reduction, intrametal electron transfer occurs within the chelated Fe(III)-doxorubicin complex itself [1]. Coordinated Fe(III) accepts an electron directly from the reduced aglycone ligand, producing coordinate Fe(II) without requiring metal dissociation [1][4]. The autonomous Fe(II)-doxorubicin conjugate acts as a persistent catalyst, continuously reducing ambient O₂ to O₂^{\bullet-} while maintaining an active redox bridge [1][2]. Table 1 benchmarks the coordination parameters, kinetic rate constants, and radical generation potentials of doxorubicin against alternative chemotherapeutic agents.
Ferritin Mobilization, Iron Regulatory Proteins, and Labile Iron Pool Expansion
Doxorubicin disrupts cellular iron homeostasis through direct organellar sequestration and post-transcriptional gene regulation [1][4]. In MDA-MB-231 breast adenocarcinoma cells and H9C2 rat embryonic cardiomyocytes, doxorubicin semiquinone radicals enter the eight hydrophilic three-fold channels of cytosolic ferritin heteropolymers [5][6]. The semiquinone donates single electrons to the internal ferrihydrite mineral core, solubilizing insoluble Fe(III) oxyhydroxide clusters and mobilizing labile ferrous iron (Fe(II)) into the cytosol [1][5]. This release circumvents the standard physiological requirement for lysosomal ferritinophagy [1].
Concurrently, doxorubicin and its secondary alcohol metabolite, doxorubicinol, alter the iron-sensing machinery orchestrated by Iron Regulatory Proteins 1 and 2 (IRP1/IRP2) [1][2]. Doxorubicin metabolites promote the oxidative disassembly of the cubane [4Fe-4S] cluster of cytosolic aconitase/IRP1, converting the enzyme into an active RNA-binding apoprotein [1][4]. Activated IRP1 binds to iron-responsive elements (IREs) situated within the 3'-untranslated region (UTR) of transferrin receptor 1 (TfR1) mRNA, preventing transcript degradation and accelerating iron import [4][5]. Conversely, binding of IRP1 to the 5'-UTR of ferritin H- and L-subunit mRNAs sterically represses ribosome scanning and halts protein translation [1][4]. Doxorubicin also downregulates the mitochondrial iron export transporter ABCB8 while impairing mitochondrial ferritin expression [4].
Quantitative fluorometric measurements using the intracellular Fe(II) sensor FerroOrange in MCF-7 adenocarcinoma and H9C2 myoblasts show an expansion of the cytosolic labile iron pool (LIP) [5][6]. Basal unchelated iron levels rise from resting physiological concentrations of <1.0 μM to 4.5 μM within 6 hours of exposure to 1.0 μM doxorubicin [5][6]. This excess cytosolic iron translocates into mitochondria via mitoferrin-1 and mitoferrin-2 transporters, concentrating transition metals at the inner membrane interface [1][4].
Kinetics of Haber-Weiss and Fenton-Driven Hydroxyl Radical Generation
The convergence of accelerated superoxide flux and mitochondrial iron accumulation establishes optimal kinetic conditions for hydroxyl radical (^{\bulletOH}) generation [1][7]. Superoxide anions produced by semiquinone redox cycling undergo enzymatic disproportionation catalyzed by mitochondrial manganese superoxide dismutase (MnSOD/SOD2) situated within the matrix, as well as copper-zinc superoxide dismutase (Cu/ZnSOD/SOD1) in the intermembrane space [1][2]. This reaction proceeds at a near-diffusion-limited rate constant (k ≈ 2 x 10[9] M^-1 s^-1), generating hydrogen peroxide (H₂O₂) and ground-state oxygen [1][7].
Matrix-accumulated Fe(II) reacts with steady-state H₂O₂ via the classic Fenton reaction, described by the stoichiometric formula:
Fe²⁺ + H₂O₂ → Fe³⁺ + ^{\bulletOH + OH^-}
This transformation proceeds with a second-order rate constant ranging between 50 and 70 M^-1 s^-1 at neutral pH [1][7]. The resulting Fe(III) product is reduced back to catalytic Fe(II) by ambient superoxide via the iron-catalyzed Haber-Weiss reaction:
O₂^{\bullet- + H2O2 ->[Fe-catalyst] ^{\bullet}OH + OH^- + O2}
This regenerative loop prevents metal self-exhaustion [1][7].
Hydroxyl radicals possess an estimated diffusion radius of <2 nm and an ultra-short half-life of 10-9 seconds, confining oxidative damage to macromolecules within immediate spatial proximity of the metal coordination site [1][7]. Electron paramagnetic resonance (EPR) spin-trapping utilizing 5,5-dimethyl-1-pyrroline N-oxide (DMPO) reveals characteristic 1:2:2:1 quartet spectra with hyperfine coupling constants of aN = aH = 14.9 G, verifying continuous hydroxyl radical production within purified mitochondrial fractions exposed to doxorubicin and ferrous sulfate [1][8]. Superoxide can also react with endogenously generated nitric oxide (^{\bulletNO}) to produce peroxynitrite (ONOO⁻), which decomposes into nitrogen dioxide and secondary hydroxyl-like radicals, amplifying tissue oxidative load [2][7].
Selective Cardiolipin Peroxidation and Mitochondrial Outer Membrane Permeabilization
Doxorubicin exhibits high selective affinity for the inner mitochondrial membrane phospholipid cardiolipin, driven by electrostatic interactions between the protonated daunosamine amine group (pKa ≈ 8.3) and the two ionized phosphate headgroups of cardiolipin (dissociation constant Kd ≈ 1.6 μM) [1][4]. This high-affinity docking concentrates doxorubicin and coordinated iron complexes within the cardiolipin-dense microenvironment surrounding respiratory electron transport complexes [1][4].
Localized hydroxyl radicals target bis-allylic methylene hydrogens residing on the polyunsaturated acyl chains of cardiolipin, particularly tetralinoleoyl cardiolipin (C18:2) [1][7]. Hydrogen abstraction initiates self-propagating free-radical chain reactions, producing cardiolipin-centered alkyl radicals, peroxyl radicals (LOO^{\bullet}), and stable cardiolipin hydroperoxides (CL-OOH) [1][7]. Non-enzymatic decomposition of these hydroperoxides yields reactive electrophilic aldehydes, predominantly 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) [7][9]. In myocardial tissues from C57BL/6 mice, 4-HNE adducts accumulate within inner mitochondrial membranes within 3 to 6 hours of doxorubicin challenge, prior to detection in cytoplasmic or nuclear compartments [7][9].
Cardiolipin peroxidation compromises mitochondrial architecture [1][4]. Peroxidized cardiolipin species aggregate into disordered lipid domains, disrupting the structural stability of respiratory Complex I, Complex III, and Complex IV supercomplexes [1][3][4]. This destabilization triggers loss of the mitochondrial transmembrane potential (ΔΨm) and impairs ATP generation [3][4]. Furthermore, cardiolipin oxidation destroys the hydrophobic anchor coordinating cytochrome c to the outer leaflet of the inner mitochondrial membrane [1][4][8]. Solubilized cytochrome c escapes through the outer membrane via Bax/Bak oligomers, activating mitochondrial outer membrane permeabilization (MOMP) and promoting downstream execution programs [1][8].
Ferroptotic Execution, GPX4 Depletion, and Dexrazoxane Chelation Dynamics
Doxorubicin-mediated cardiolipin and phospholipid peroxidation converges on non-apoptotic ferroptosis, a regulated necrotic modality dependent on iron-catalyzed lipid peroxidation [1][5][6]. In isolated H9C2 cardiomyocytes, doxorubicin exposure causes severe depletion of reduced glutathione (GSH), driving the physiological GSH:GSSG ratio down from 100:1 to less than 10:1 [6][9]. This intracellular thiol depletion deprives selenium-dependent glutathione peroxidase 4 (GPX4) of its obligate reducing cofactor [1][6]. Without active GPX4, toxic phospholipid hydroperoxides remain unreduced, inducing severe inner and outer membrane rupture [1][5]. Pharmacological studies demonstrate that the ferroptosis-specific radical-trapping antioxidants ferrostatin-1 (1 μM) and liproxstatin-1 (500 nM) restore cardiomyocyte viability, whereas the pan-caspase inhibitor Z-VAD-FMK exhibits incomplete cytoprotection [1][6].
Clinical and experimental mitigation of this cascade relies on dexrazoxane (ICRF-187) [1][8]. Dexrazoxane diffuses across cellular and mitochondrial membranes, where dihydropyrimidine amidohydrolase hydrolyzes its bis-dioxopiperazine rings into the open-ring active metabolite ADR-925 [1][8]. ADR-925 functions as a multidentate chelator that binds Fe(III) and Fe(II) with affinities that outcompete the doxorubicin aglycone, effectively displacing the metal and stripping the anthracycline core of its catalytic partner [1][8]. Stoichiometrically, complete suppression of hydroxyl radical evolution and cardiolipin peroxidation requires a 10:1 to 20:1 molar ratio of dexrazoxane to doxorubicin [1][8]. In addition to iron chelation, dexrazoxane binds to the ATP-binding pocket of Topoisomerase IIβ, locking the homodimer in a closed, non-cleavable conformation that prevents anthracycline-induced double-strand DNA breaks [1][8]. This dual activity positions dexrazoxane as an effective pharmacological antagonist against both topoisomerase-mediated genotoxicity and transition-metal-driven ferroptosis [1][8].